• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Zimmer Biomet fights below-market mini-tender

Zimmer Biomet fights below-market mini-tender

July 30, 2019 By Brad Perriello

Zimmer Biomet logoZimmer Biomet (NYSE:ZBH) is advising its stockholders not to pick up a below-market mini-tender offer from TRC Capital, that firm’s latest attempt to pick up a medtech stock on the cheap.

TRC is offering to buy up to 1 million ZBH shares at $115.35 apiece – 4.4% lower that their $120.60 closing price the day before the mini-tender offer and 14.2% off the $134.50 closing price July 26.

“Zimmer Biomet does not endorse TRC’s unsolicited mini-tender offer and recommends that shareholders not tender their shares in response to the offer. The offer was commenced at a below-market offer price, is highly conditional and is not subject to important investor protections. Zimmer Biomet is not affiliated or associated in any way with TRC, its mini-tender offer or the offer documentation,” the company said. “Zimmer Biomet urges investors to obtain current market quotations for their shares, to review the conditions of TRC’s mini-tender offer, to consult with their brokers or financial advisors and to exercise caution with respect to TRC’s offer.”

Shareholders who already bit on the offer have until August 13 to withdraw via written notice, Warsaw, Ind.-based Zimmer Biomet said.

It’s not the first time TRC has tried the below-market mini-tender gambit. In February 2014 the company offered to buy back Intuitive Surgical (NSDQ:ISRG) shares at $405 a pop, which at the time was about 6.4% lower than the stock’s 12-month average closing price.

An offer to acquire 2 million Cardinal Health (NYSE:CAH) shares at about 5% below their market price followed last year. And just last month TRC was looking to purchase approximately 1 million shares of Edwards Lifesciences (NYSE:EW) stock at $162.38 each, about 3.8% off their closing price the day before.

ZBH shares were trading at $135.55 apiece today in early-afternoon activity, up 0.8%.

Filed Under: Orthopedics, Wall Street Beat Tagged With: Zimmer Biomet

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy